Following on from the phenomenal success of a portfolio of international pharmaceutical events, including our flagship annual European Biosmilars and Biobetters conference, we bring you this exciting, timely and important conference.
As the expiration of patent protection for several top-selling biologicals over the next decade draws closer, this is predicted to open up an estimated US$24 billion in EU sales and US$30 billion in US sales of biosimilars. With the potentially rapid growth of this market, biosimilar manufacturers are set to make a ‘beeline’ towards this lucrative opportunity.
Despite having to overcome a number of commercial, regulatory, financial and business challenges, the anticipated establishment of robust FDA regulatory guidelines, coupled with the economic need for cheaper biological drugs is expected to add momentum to the growth of the USA biosimilars industry.
This superb networking event will invite in-depth discussion of key industry issues and drivers central to biosimilars including cost effective development and process methods, implementation of clinical trials, evaluating safety and quality, as well as regulatory and legal preparedness.
Through a series of exciting panel discussions, presentations and workshops, delivered by true industry experts and players, the Biosimilars and Biobetters USA conference will offer strategies and solutions for developing cost effective biosimilars. Do not miss this opportunity to network, establish new connections, exchange ideas and gain knowledge as we explore the future opportunities of biosimilars and biobetters in 2014!